AnHeart Therapeutics has announced the signing of agreements that will allow the company to achieve over 20 million USD of fund under an financing round of over-subscribed Series A+ equity .
The company would use the proceeds envisioned to receive from financing will allow the advancement of its taletrectinib’s global Phase 2 trials, which is a potent and highly selective next generation ROS1/NTRK inhibitor and further expanding the AnHeart’s oncology portfolio.
The financing will help the AnHeart to execute its global development plan that it purposed for taletrectinib, and bring the advancement in differentiated cancer drug that large number of NSCLC patients with ROS1 and NTRK mutations could utilize. The company has also the aim to expand itself into other oncology adjacencies to deepen our pipeline over time and where the company can have a competitive advantage.
PhD, Chief Executive Officer of AnHeart, Junyuan (Jerry) Wang said “We desire to expand into other oncology adjacencies where we may have a competitive advantage and to deepen our pipeline over time. We value the support of our experienced and esteemed investors to help us execute on our vision.”
Taletrectinib is the lead clinical candidate which has aim to become a next-generation, potent, highly selective ROS1 and NTRK inhibitor that puposes the crossing of blood-brain barrier. While AnHeart Therapeutics is a clinical stage oncology company which focuses on underserved patients in global markets.